1499514920
The Uromigos

Advertise on podcast: The Uromigos

Rating
★★★★★
4.8
from
66 reviews
This podcast has
506 episodes
Language
English
Publisher
The Uromigos
Explicit
No
Date created
2020/02/18
Latest episode
2026/11/15
Average duration
40 min.
Release period
2 days

Description

Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

Unlock The Uromigos podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Podcast episodes

Check latest episodes from The Uromigos podcast


Episode 540 - Uromigos Live 2026 – T Cell Engagers in RCC: Have We Finally Turned a Corner?
2026/11/15
The final session of this year’s meeting discusses exciting T cell engager and CAR-T data from ESMO 2026. Are these approaches finally ready for prime time in mRCC?
Episode 539 - Uromigos Live 2026 – Are Doublets the New Standard of Care Throughout the RCC Continuum?
2026/11/15
Doublet therapy has produced positive results in the adjuvant and refractory RCC settings. Are they the standard of care and what is the role of monotherapy for individual patients?
Episode 538 - Uromigos Live 2026 – Triplet Therapy in mRCC: What Went Wrong?
2026/11/15
Recent attempts to build on the IO-doublet backbone in front-line clear cell RCC therapy have failed including LITESPARK-012. The panel discusses issues that have impacted these trials and where we go from here.
Episode 537 - Uromigos Live 2026 – Sequencing of Therapy Across the Continuum of Advanced Prostate Cancer
2026/11/14
Several third agents added to the ADT/ARPI backbone in mHSPC have emerged in the last year including radioligands and PARP inhibitors. Navigating application to individual patients is discussed by our expert panel.
Episode 536 - Uromigos Live 2026 – High-risk Localized Prostate Cancer
2026/11/14
Several phase 3 trials in high-risk localized prostate cancer have reported this year including PROTEUS and DASL. The panel debates if and how these will impact treatment of this patient population.
Episode 535 - Uromigos Live 2026 – MIBC: The Evolution of Antibody Drug Conjugates (ADCs) in Bladder Cancer
2026/11/14
ADCs have become a mainstay of systemic therapy in bladder cancer. Where are we headed next? The panel discusses issues around target, payload and sequencing.
Episode 534 - Uromigos Live 2026 – MIBC: What is the necessity of bladder-directed therapy?
2026/11/14
The emergence of highly active systemic therapy in the MIBC setting has challenged the notion that all patients need cystectomy or chemoradiation. Our live panel debates this thorny issue.
Episode 533 - Uromigos Live 2026 – MIBC: Does ctDNA and/or utDNA Have a Role?
2026/11/14
The panel discusses emerging data on if and how ctDNA and urinary tumor DNA (utDNA) can be incorporated into prognostication and treatment decisions.
Episode 532 - Uromigos Live 2026 – MIBC: How Does VOLGA Change the Landscape?
2026/11/14
The VOLGA trial was presented at ESMO 2026 and challenged the necessity of adjuvant therapy in MIBC. The panel discusses how these critical data impact the landscape.
Episode 531 - Uromigos Live 2026 – MIBC: What is the Role of Platinum-based Chemotherapy and/or Immune Therapy?
2026/11/14
This kickoff session at this year’s live meeting looks at whether chemotherapy and immune therapy outside of EVP have a role in MIBC.
Episode 530: ESMO 2026 Review
2026/11/02
Silke, Brian and Tom review exciting ESMO 2026 data in GU Oncology and more.
Episode 529: ESMO 2026 - LITESPARK-011 Updated Results including Overall Survival
2026/10/25
Danny Heng joins the show to discuss his ESMO 2026 presentation of LITESPARK-011 and the OS data. Published today in Annals of Oncology!
Episode 528: ESMO 2026 - LITESPARK 012
2026/10/25
Martin Voss takes on the role of Host and interviews Brian and Tom about this phase 3 study of triplets in metastatic ccRCC. Published today in Annals of Oncology!
Episode 527: ESMO 2026 - DASL-HiCaP Adding Darolutamide to ADT and XRT in High-risk Localized Prostate Cancer
2026/10/24
Chris Sweeney discusses this ANZUP trial which adds more phase 3 data to the high risk prostate cancer space.
Episode 526: ESMO 2026 - The VOLGA trial in MIBC
2026/10/24
Michiel Van Der Heijden joins us after his ESMO discussion and Tom's presentation to discuss how these critical data reshape the MIBC landscape.

Podcast reviews

Read The Uromigos podcast reviews


4.8 out of 5
66 reviews
★★★★★
gERDorNerd 2026/10/14
Amazing information!
I am no medical doctor but a PhD researcher in big pharma. Love the details and makes you keep updated with the latest medical findings. Will help if ...
★★★★★
Tea Green 2025/10/03
Excellent resource for patients anddocs
The Uromigos keep patients and doctors informed with the very latest studies and research in urogenital cancer. I appreciate their hopeful, upbeat an...
★★★★★
Attentive listener 12345 2024/02/11
Great for staying up on GU oncology
Drs. Powles and Rini are some of the most eminent current leaders in GU oncology. In this podcast, they discuss recent key studies in the field and re...
★★★★★
Jacky4911 2021/06/08
Fantastic podcast
This is a fantastic podcast! Great insight with provocative discussions (while keeping it lighthearted at the same time).... Thank you guys. Keep the...
★★★★★
JJHam 2020/10/08
Thoughtful discussion of data
Thank you for the thoughtful and humorous discussion of recent publications. Keep it going!!
★★★★★
Yulia44 2020/03/03
Great discussion!
This is a great series with insightful analysis of the data from recent clinical trials.
check all reviews on apple podcasts

Podcast sponsorship advertising

Start advertising on The Uromigos relevant audience podcasts


What do you want to promote?